Goetz C G, Tanner C M, Glantz R H, Klawans H L
Neurology. 1985 May;35(5):749-51. doi: 10.1212/wnl.35.5.749.
We used pergolide to treat 10 patients with idiopathic Parkinson's disease who had first responded to, and then failed, bromocriptine therapy. At the end of 5 years, patients had improved when compared with study entry. Peak efficacy, equal with both drugs, was seen at 12 months. After a mean treatment of 29 months, bromocriptine was no longer effective, but pergolide was still beneficial.
我们使用培高利特治疗10例特发性帕金森病患者，这些患者最初对溴隐亭治疗有反应，但后来治疗失败。在5年结束时，与研究开始时相比，患者病情有所改善。两种药物的疗效峰值均在12个月时出现。经过平均29个月的治疗后，溴隐亭不再有效，但培高利特仍有疗效。
